Public Sector Pension Investment Board Sells 4,000 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Public Sector Pension Investment Board lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 116,949 shares of the specialty pharmaceutical company’s stock after selling 4,000 shares during the period. Public Sector Pension Investment Board’s holdings in Supernus Pharmaceuticals were worth $3,646,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC grew its stake in shares of Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Supernus Pharmaceuticals during the second quarter worth $47,000. Innealta Capital LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Supernus Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock worth $61,000 after purchasing an additional 352 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Supernus Pharmaceuticals in the second quarter worth $72,000.

Insider Activity

In other news, Director Georges Gemayel sold 14,213 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.62, for a total transaction of $520,480.06. Following the transaction, the director now owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 51.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jack A. Khattar sold 125,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now owns 926,172 shares in the company, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 154,213 shares of company stock worth $5,660,180. Company insiders own 9.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 2.0 %

SUPN stock opened at $37.31 on Tuesday. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 34.87 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $39.37. The company’s fifty day simple moving average is $34.20 and its 200 day simple moving average is $31.35.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.29) earnings per share. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.